“Using our DCF model and a calculated WACC of 6,9 %, we determine a fair value of CZK 300 and a 12-month price target of CZK 321,” notes Dr. Kalliwoda Research GmbH in analytical report GEVORKYAN, a.s. Initiation of Coverage H1 2025, dated November 10, 2025.
GEVORKYAN, a.s. announces an update of the independent analyst coverage of its shares.
Dr. Kalliwoda Research has published its analysis based on strong results for the first half of 2025, which were announced on September 17, 2025:
https://kalliwoda.com/pdf/Gevorkyan25.pdf.
According to the analytical report, GEVORKYAN, a.s. achieved revenues of EUR 42.2 million (+11% year-on-year) and EBITDA of EUR 13.8 million (+15%) in the first half of 2025. The target share price…
